Jeffrey J. Denning
Contributing Editor

Under capitation, a medical practice's earnings don't rise directly with its production. That doesn't mean, says this consultant, that productivity payment systems for individual physicians should be junked.

Jeffrey J. Denning

Contributing Editor

A medical group I know is positioning itself for capitation. Its members have no experience with capitation payment, but, from what they have heard, the idea is to avoid rewarding a physician for doing a lot of work, since the payment to a practice is independent of what services are actually rendered each month.

The group, therefore, has adopted a new formula in which a significant share of each doctor's income — rising as capitation comes to dominate practice receipts — is determined on a straight-salary basis irrespective of productivity. The group hopes the new formula will encourage internal referrals, allowing more effective subspecialty development and less competition for highly remunerative cases. All sounds plausible, no?

Here's the catch: The assumptions are wrong.

Wrong Assumption 1: Physicians are only competitive when it comes to money. Nobody gets into medicine by being noncompetitive. Everything physicians do is competitive, from comparing OR time to crossing the street.

Wrong Assumption 2: There is something wrong with competition. Sure, predatory competition that involves cheating is unconscionable. But striving for excellence, including high earnings, is what pushes the best groups to better themselves each year.

Wrong Assumption 3: High productivity will somehow jeopardize group performance.

Most folks agree that encouraging conservative, cost-effective care is what capitation payment is designed to do. Because you're paid the same whether you do surgery or just prescribe a change in life style, physicians are encouraged to do what is necessary for the well-being of the patient, not what results in the highest fee.

But getting a good outcome and top-quality care still matters to the patients — all of them. A pay system that tempts doctors to cut corners isn't going to work either. Not in the long run.

Work done per hour

What is needed is an environment in which physicians are encouraged to be highly productive without wasting costly resources like MRI machines, operating theaters and consulting cardiologists. Higher production is still a winner if one considers the doctor as the highest-cost resource in the medical practice.

Much of the pressure to switch from productivity to flat salaries is to prevent "gaming" of the system. Suddenly, partners are in the awkward position of health insurance medical directors, fearful that colleagues will overtreat patients if they are rewarded on production.

Abuses must be avoided, certainly. But abandoning an income mechanism that is largely responsible for the highest productive physician capacity in the world seems wrong. And there is plenty of evidence that paying physicians equally or for something other than work output results in lower practice efficiency and lower output.

The author, a practice management consultant in Long Beach, Calif., edits Uncommon Sense, a monthly newsletter for physicians.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.